CEACAM5 and cancer: The data revealed that patients in CD16low/− group had more cancer recurrence (P = 0.042) and high level of carcinoembryonic antigen (CEA) (P = 0.023) as well as carbohydrate antigen 199 (CA199) (P = 0.016) compared to patients in CD16+ group (Table 2).